Profitability
Weight: 25%
D-
30
- 5yr Avg ROIC -57.6%
- Operating Margin Trend +26.45 pp/yr
PTCT
PTC Therapeutics, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
6
- 5yr Avg ROE 0.0%
- 5yr Share-Count CAGR 5.8%
Growth Quality
Weight: 25%
B-
68
- 5yr Revenue CAGR 33.9%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 4/5
Cash Generation
Weight: 20%
C-
45
- 5yr FCF Margin -29.4%
- 5yr FCF/NI Conversion 1.03x
Balance Sheet
Weight: 10%
B-
67
- Net Debt / EBITDA -1.64x
- Interest Coverage (EBIT/Int) 5.58x
- Altman Z-Score 0.44
Stability
Weight: 5%
B-
68
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 1
- Negative-Revenue Years (5) 1/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 4 gurus held; 1 trimmed; 3 full exits.
- Holders
- 1 -3
- Avg Δ position
- -6.0%
- New buys
- 0
- Full exits
- 3
- Dalio sold -100%
- Greenblatt sold -100%
- Wood sold -100%